Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accounts Payables (2023 - 2025)

Immunome (IMNM) has disclosed Accounts Payables for 3 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 76.47% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Dec 2025, down 76.47%, and an annual FY2025 reading of $3.3 million, down 76.47% over the prior year.
  • Accounts Payables was $3.3 million for Q4 2025 at Immunome, down from $6.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $14.2 million in Q4 2024 and bottomed at $2.8 million in Q3 2023.
  • Average Accounts Payables over 3 years is $5.7 million, with a median of $4.2 million recorded in 2023.
  • The sharpest move saw Accounts Payables surged 328.54% in 2024, then plummeted 76.47% in 2025.
  • Year by year, Accounts Payables stood at $3.3 million in 2023, then soared by 328.54% to $14.2 million in 2024, then tumbled by 76.47% to $3.3 million in 2025.
  • Business Quant data shows Accounts Payables for IMNM at $3.3 million in Q4 2025, $6.1 million in Q3 2025, and $4.7 million in Q2 2025.